...
首页> 外文期刊>International Journal of Cancer =: Journal International du Cancer >Identification of G0S2 as a gene frequently methylated in squamous lung cancer by combination of in silico and experimental approaches.
【24h】

Identification of G0S2 as a gene frequently methylated in squamous lung cancer by combination of in silico and experimental approaches.

机译:用三硅和实验方法的组合鉴定G0S2作为鳞状肺癌常规甲基化的基因。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Epigenetic changes can lead to abnormal expression of genes in cancer, and several genes have been reported to have aberrant promoter DNA methylation in non-small-cell lung cancer (NSCLC). We identified aberrantly methylated genes in NSCLC by combination of in silico and experimental approaches. We first applied bioinformatics, and from microarray datasets, we selected genes with low expression and having functions related to cancer. Next, combined bisulfite restriction analysis was carried out in 10 pooled resected lung cancer tissues to screen for genes that were aberrantly methylated, and the methylation ratio (the fraction of methylated DNA in extracted DNA from a cancer tissue sample) was quantified using quantitative analysis of methylated alleles. We identified 8 methylated genes (ARPC1B, DNAH9, FLRT2, G0S2, IRS2, PKP1, SPOCK1 and UCHL1) previously unreported in NSCLC. Analyses of methylation profiles of 101 resected lung cancer tissue samples revealed quantitatively low methylation in whole, methylation ratios were almost less than 30% even in the methylated samples, and no significant correlation to prognosis after 2 years of follow-up using hierarchical clustering. DNA methylation of G0S2 gene was significantly more frequent in squamous lung cancer (n = 18, mean of methylation ratios: 15%) compared with nonsquamous lung cancer (n = 83, mean of methylation ratios: 2.6%) (Mann-Whitney U test, p < 0.001). DNA methylation of G0S2 can be an important biomarker for squamous lung cancer.
机译:表观遗传变化可导致癌症中基因的异常表达,并且据报道了几种基因在非小细胞肺癌(NSCLC)中具有异常启动子DNA甲基化。我们通过在硅和实验方法中结合鉴定了NSCLC中的异常甲基化基因。我们首先应用生物信息学,以及微阵列数据集,我们选择了低表达的基因并具有与癌症相关的功能。接下来,将合并的亚硫酸氢盐限制分析在10个合并的切除的肺癌组织中进行,以用于异常甲基化的基因,并且使用定量分析定量甲基化比(从癌组织样品中提取的DNA中的甲基化DNA的级分)甲基化等位基因。我们鉴定了先前未报告的NSCLC先前未报告的甲基化基因(ARPC1B,DNAH9,FLRT2,GOS2,IRS2,PKP1,SPOCK1和UCHL1)。在甲基化样品中,101分切肺癌组织样品的甲基化型甲基化型甲基化型甲基化型的分析几乎小于30%,并且在使用等级聚类后2年后与预后的显着相关性。与非应燃肺癌(n = 83,甲基化比例:2.6%)(Mann-Whitney US)相比,G0S2基因的DNA甲基化在鳞状癌(N = 18,甲基化比例:15%)中显着更频繁地频繁,p <0.001)。 G0S2的DNA甲基化可以是鳞状肺癌的重要生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号